Overview of lupus nephritis management guidelines and perspective from Asia

Chi Chiu Mok, Desmond Y H Yap, Sandra V. Navarra, Zhi Hong Liu, Ming Hui Zhao, Liangjing Lu, Tsutomu Takeuchi, Yingyos Avihingsanon, Xue Qing Yu, Elizabeth A. Lapid, Lenrore R. Lugue-Lizardo, Vasant Sumethkul, Nan Shen, Shun Le Chen, Tak Mao Chan

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Lupus nephritis (LN) is a common and important manifestation of systemic lupus erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethnic groups. The management of LN has evolved considerably over the past three decades, based on observations from clinical studies that investigated different immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, mycophenolic acid, calcineurin inhibitors and novel biologic therapies. This is accompanied by improvements in both the short-term treatment response rate and long-term renal function preservation. Treatment guidelines for LN have recently been issued by rheumatology and nephrology communities in U.S.A. and Europe. In view of the racial difference in disease manifestation and response to therapy, and the substantial disease burden in Asia, a panel of 15 nephrologists and rheumatologists from different Asian regions with extensive experience in lupus nephritis - the Steering Group for the Asian Lupus Nephritis Network (ALNN) - met and discussed the management of lupus nephritis in Asian patients. The group has also reviewed and deliberated on the recently published recommendations from other parts of the world. This manuscript summarizes the discussions by the group and presents consensus views on the clinical management and treatment of adult Asian patients with LN, taking into account both the available evidence and expert opinion in areas where evidence remains to be sought.

Original languageEnglish
Pages (from-to)11-20
Number of pages10
JournalNephrology
Volume19
Issue number1
DOIs
Publication statusPublished - 2014 Jan

Fingerprint

Lupus Nephritis
Guidelines
Mycophenolic Acid
Kidney
Biological Therapy
Nephrology
Nephritis
Azathioprine
Expert Testimony
Rheumatology
Therapeutics
Immunosuppressive Agents
Ethnic Groups
Systemic Lupus Erythematosus
Cyclophosphamide
Adrenal Cortex Hormones
Population

Keywords

  • Asia
  • lupus
  • nephritis

ASJC Scopus subject areas

  • Nephrology

Cite this

Mok, C. C., Yap, D. Y. H., Navarra, S. V., Liu, Z. H., Zhao, M. H., Lu, L., ... Chan, T. M. (2014). Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology, 19(1), 11-20. https://doi.org/10.1111/nep.12136

Overview of lupus nephritis management guidelines and perspective from Asia. / Mok, Chi Chiu; Yap, Desmond Y H; Navarra, Sandra V.; Liu, Zhi Hong; Zhao, Ming Hui; Lu, Liangjing; Takeuchi, Tsutomu; Avihingsanon, Yingyos; Yu, Xue Qing; Lapid, Elizabeth A.; Lugue-Lizardo, Lenrore R.; Sumethkul, Vasant; Shen, Nan; Chen, Shun Le; Chan, Tak Mao.

In: Nephrology, Vol. 19, No. 1, 01.2014, p. 11-20.

Research output: Contribution to journalArticle

Mok, CC, Yap, DYH, Navarra, SV, Liu, ZH, Zhao, MH, Lu, L, Takeuchi, T, Avihingsanon, Y, Yu, XQ, Lapid, EA, Lugue-Lizardo, LR, Sumethkul, V, Shen, N, Chen, SL & Chan, TM 2014, 'Overview of lupus nephritis management guidelines and perspective from Asia', Nephrology, vol. 19, no. 1, pp. 11-20. https://doi.org/10.1111/nep.12136
Mok CC, Yap DYH, Navarra SV, Liu ZH, Zhao MH, Lu L et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology. 2014 Jan;19(1):11-20. https://doi.org/10.1111/nep.12136
Mok, Chi Chiu ; Yap, Desmond Y H ; Navarra, Sandra V. ; Liu, Zhi Hong ; Zhao, Ming Hui ; Lu, Liangjing ; Takeuchi, Tsutomu ; Avihingsanon, Yingyos ; Yu, Xue Qing ; Lapid, Elizabeth A. ; Lugue-Lizardo, Lenrore R. ; Sumethkul, Vasant ; Shen, Nan ; Chen, Shun Le ; Chan, Tak Mao. / Overview of lupus nephritis management guidelines and perspective from Asia. In: Nephrology. 2014 ; Vol. 19, No. 1. pp. 11-20.
@article{fb749f96c5f74d7f8ea75974f1189c11,
title = "Overview of lupus nephritis management guidelines and perspective from Asia",
abstract = "Lupus nephritis (LN) is a common and important manifestation of systemic lupus erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethnic groups. The management of LN has evolved considerably over the past three decades, based on observations from clinical studies that investigated different immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, mycophenolic acid, calcineurin inhibitors and novel biologic therapies. This is accompanied by improvements in both the short-term treatment response rate and long-term renal function preservation. Treatment guidelines for LN have recently been issued by rheumatology and nephrology communities in U.S.A. and Europe. In view of the racial difference in disease manifestation and response to therapy, and the substantial disease burden in Asia, a panel of 15 nephrologists and rheumatologists from different Asian regions with extensive experience in lupus nephritis - the Steering Group for the Asian Lupus Nephritis Network (ALNN) - met and discussed the management of lupus nephritis in Asian patients. The group has also reviewed and deliberated on the recently published recommendations from other parts of the world. This manuscript summarizes the discussions by the group and presents consensus views on the clinical management and treatment of adult Asian patients with LN, taking into account both the available evidence and expert opinion in areas where evidence remains to be sought.",
keywords = "Asia, lupus, nephritis",
author = "Mok, {Chi Chiu} and Yap, {Desmond Y H} and Navarra, {Sandra V.} and Liu, {Zhi Hong} and Zhao, {Ming Hui} and Liangjing Lu and Tsutomu Takeuchi and Yingyos Avihingsanon and Yu, {Xue Qing} and Lapid, {Elizabeth A.} and Lugue-Lizardo, {Lenrore R.} and Vasant Sumethkul and Nan Shen and Chen, {Shun Le} and Chan, {Tak Mao}",
year = "2014",
month = "1",
doi = "10.1111/nep.12136",
language = "English",
volume = "19",
pages = "11--20",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Overview of lupus nephritis management guidelines and perspective from Asia

AU - Mok, Chi Chiu

AU - Yap, Desmond Y H

AU - Navarra, Sandra V.

AU - Liu, Zhi Hong

AU - Zhao, Ming Hui

AU - Lu, Liangjing

AU - Takeuchi, Tsutomu

AU - Avihingsanon, Yingyos

AU - Yu, Xue Qing

AU - Lapid, Elizabeth A.

AU - Lugue-Lizardo, Lenrore R.

AU - Sumethkul, Vasant

AU - Shen, Nan

AU - Chen, Shun Le

AU - Chan, Tak Mao

PY - 2014/1

Y1 - 2014/1

N2 - Lupus nephritis (LN) is a common and important manifestation of systemic lupus erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethnic groups. The management of LN has evolved considerably over the past three decades, based on observations from clinical studies that investigated different immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, mycophenolic acid, calcineurin inhibitors and novel biologic therapies. This is accompanied by improvements in both the short-term treatment response rate and long-term renal function preservation. Treatment guidelines for LN have recently been issued by rheumatology and nephrology communities in U.S.A. and Europe. In view of the racial difference in disease manifestation and response to therapy, and the substantial disease burden in Asia, a panel of 15 nephrologists and rheumatologists from different Asian regions with extensive experience in lupus nephritis - the Steering Group for the Asian Lupus Nephritis Network (ALNN) - met and discussed the management of lupus nephritis in Asian patients. The group has also reviewed and deliberated on the recently published recommendations from other parts of the world. This manuscript summarizes the discussions by the group and presents consensus views on the clinical management and treatment of adult Asian patients with LN, taking into account both the available evidence and expert opinion in areas where evidence remains to be sought.

AB - Lupus nephritis (LN) is a common and important manifestation of systemic lupus erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian populations, and maybe more severe nephritis, compared with other racial or ethnic groups. The management of LN has evolved considerably over the past three decades, based on observations from clinical studies that investigated different immunosuppressive agents including corticosteroids, cyclophosphamide, azathioprine, mycophenolic acid, calcineurin inhibitors and novel biologic therapies. This is accompanied by improvements in both the short-term treatment response rate and long-term renal function preservation. Treatment guidelines for LN have recently been issued by rheumatology and nephrology communities in U.S.A. and Europe. In view of the racial difference in disease manifestation and response to therapy, and the substantial disease burden in Asia, a panel of 15 nephrologists and rheumatologists from different Asian regions with extensive experience in lupus nephritis - the Steering Group for the Asian Lupus Nephritis Network (ALNN) - met and discussed the management of lupus nephritis in Asian patients. The group has also reviewed and deliberated on the recently published recommendations from other parts of the world. This manuscript summarizes the discussions by the group and presents consensus views on the clinical management and treatment of adult Asian patients with LN, taking into account both the available evidence and expert opinion in areas where evidence remains to be sought.

KW - Asia

KW - lupus

KW - nephritis

UR - http://www.scopus.com/inward/record.url?scp=84890488736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890488736&partnerID=8YFLogxK

U2 - 10.1111/nep.12136

DO - 10.1111/nep.12136

M3 - Article

VL - 19

SP - 11

EP - 20

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 1

ER -